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Abstract
Oncoproteomics is an important innovation in the early diagnosis, management and development of personalized treatment of acute lympho-
blastic leukaemia (ALL). As inherent factors are not completely known – e.g. age or family history, radiation exposure, benzene chemical expo-
sure, certain viral exposures such as infection with the human T-cell lymphoma/leukaemia virus-1, as well as some inherited syndromes may
raise the risk of ALL – each ALL patient may modify the susceptibility of therapy. Indeed, we consider these unknown inherent factors could be
explained via coupling cytogenetics plus proteomics, especially when proteins are the ones which play function within cells. Innovative proteo-
mics to ALL therapy may help to understand the mechanism of drug resistance and toxicities, which in turn will provide some leads to improve
ALL management. Most important of these are shotgun proteomic strategies to unravel ALL aberrant signalling networks. Some shotgun prote-
omic innovations and bioinformatic tools for ALL therapies will be discussed. As network proteins are distinctive characteristics for ALL
patients, unrevealed by cytogenetics, those network proteins are currently an important source of novel therapeutic targets that emerge from
shotgun proteomics. Indeed, ALL evolution can be studied for each individual patient via oncoproteomics.
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Introduction
Early accurate diagnosis and personalized treatment are essential to
treat complex and fatal diseases such as cancer. New paradigms are
emerging for innovations on therapies, especially for chronic and
malignant diseases such as acute lymphoblastic leukaemia (ALL) via
shotgun proteomics [1].
ALL can be classified via cytogenetic and molecular subgroups
for diagnosis, prognosis, and more importantly, for the application of
the correct treatment. A remarkable but common in patients with ALL
is the appearance of resistance against drugs/therapies. Mutations,
genetic aberrations (Table 1) [2–5], cellular heterogeneity of ALL
after initial response to therapy and deregulation of signalling net-
works (unknown for ALL patients with poor responses) play impor-
tant roles in ALL resistance therapies [6].
Aberrant proteins and signalling networks of ALL evolution can be
addressed directly from human body fluids via state of art shotgun
oncoproteomics. This makes it possible to get the molecules which
are not working well or are mutating (space, time) during ALL treat-
ments of each patient. This allows detection of the molecular differ-
ences between patients with good response to ALL therapies and
patients with poor response. ‘Omics’ shotgun oncoproteomic technol-
ogies coupled to cytogenetics are used today in integrated
approaches to clarify ALL for future therapy innovations which will
benefit ALL patients [7].
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For integrating hundreds or thousands of proteomic signatures
from ALL patients’ evolution, bioinformatic tools offer different
software to create an ALL ‘library’ to link biological discoveries for
new drug designs [8].
ALL treatments tend to be
personalized via proteomics
innovations
With the completion of the human genome project, standard ALL
treatments may be adjusted by genetic mutations, including single
nucleotide polymorphisms in predicting patient responses (Table 1).
In broad sense, individualized medicine is not new, but the options
and perspectives have been widely expanded within the last decade
via omics innovations, including shotgun proteomics, especially when
genetic profiles of each ALL patient may modify the susceptibility of
therapy [9].
Generally, ALL antimetabolites induce cell death during the S
phase of cell growth when incorporated into RNA and DNA or inhibit
enzymes needed for nucleic acid production. The drawback involved
is that currently, despite the tremendous advances in ALL treatments,
patients still suffer from different degree of side effects, toxicities and
resistances of treatments [10].
Risk-based ALL therapy (chemotherapy) is emphasized in thera-
peutic protocols to reduce the toxicity of treatments in patients with
good prognosis and provide aggressive therapies for those with poor
prognosis. Taken into consideration in the risk stratification include
age, initial white blood cells, ALL subtype, chromosomal aberrations
or minimal residual disease, although the exact signatures for
relapses remain unknown. Chemotherapy and bone marrow
transplant are included in the treatment of relapse dependant on
those prognostic factors for patients with high risk of early and late
relapses with low chemotherapy response. Improved ALL cure rates
during the last decades suggest that many relapses in the past were
insufficiently treated, in part because of variations in drug disposition,
rather than being a reflection of treatment resistance [11].
Central nervous system-directed treatment, and antimetabolite-
based maintenance therapy with 6-mercaptopurine (6-MP) and meth-
otrexate, which are continued for up to 2–3 years after diagnosis, is
believed to be of major importance for the improved rates of ALL cure
[12].
The cytotoxicity of methotrexate relies on cellular depletion of tet-
rahydrofolates leading to inhibition of nucleotide de novo synthesis
and amino acid metabolism. Upon intake, 6-MP may become inacti-
vated through methylation by thiopurine methyltransferase. Some
methylated 6-MP metabolites (e.g. 6-methylthioinosine-monophso-
phate) also inhibit nucleotide de novo synthesis. However, the main
cytotoxic effect relies on the purine salvage pathway and kinase-med-
iated multi-step conversion of 6-MP into 6-thioguanosine nucleotides,
which are subsequently incorporated into DNA. Cellular recognition of
the resulting nucleobase mismatches induces apoptosis. Thus, inno-
vations in ALL drugs may be achieved via shotgun oncoproteomics
when mapping the aberrant signalling networks in ALL [13].
Regardless of statistical significance and degree of mechanistic
understanding of genotype–phenotype associations, their clinical
applicability should be tested in prospective randomized clinical trials.
For example, the profile of toxicities in childhood ALL therapy is broad
and a limited number of patients are available, it is unrealistic to per-
form randomized clinical trials for each toxicity, and it is, furthermore,
difficult to obtain sufficient statistical power to demonstrate changes
in the frequency of rare toxicities. The division of patients into multi-
ple risk groups and the late occurrence of many events further burden
such trials. Nevertheless, addressing multiple toxicities and allowing
genotype and omics-proteomics-based adjustments of several anti-
cancer agents to reduce the burden of therapy and simultaneously
improve cure rates, may be a proof-of-concept approach even though
the subsequent statistical and pharmaceutical, plus biological identifi-
cation, of the most important treatment modifications is a difficult but
possible challenge [14].
Proteomics-based studies for
the improvements of ALL therapy
Accordi et al. [11] applied reverse phase protein microarrays to iden-
tify active-mutated proteins in 118 paediatric B-cell precursor (BCP)-
ALL patients. In this study, 92 key signalling proteins have been
shown to be activated for this pathology via phosphoproteomics. The
involved pathways are related to cell proliferation in patients with poor
prognosis. BCL-2 is hyperphosphorylated via AMPK activation in
MLL-rearranged patients. AMPK could have an important role for
Table 1 Common acute lymphoblastic leukaemia translocations and
cytogenetic abnormalities (http://emedicine.medscape.com/article/
207631-workup#a0756) [2–5]
Mutation
Related
genes
Survival after
2–3 years (%)
t(10,14)(q24;q11) HOX11/TCRA 75
6q Unknown 47
14q11 TCRA/TCRD 42
11q23 MLL 18–26
9p Unknown 22
12 TEL 20
t(1;19)(q23;p13) PBX1/E2A 20
t(8;14)(q24;q32) c-myc/IGH 17
t(2;8)(p12;q24) IGK/c-myc 80
t(8;22)(q24;q11) c-myc/IGL 5–10
t(9;22)(q34;q11) bcr-abl 66
t(4;11)(q21;q23) AF4-MLL 0–10
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inhibition of apoptosis in these patients. This is an important issue for
innovations in ALL therapy. In addition, Accordi et al. [11] realized
that prednisone is up-modulating the LCK proto-oncogene, Src family
tyrosine kinase (LCK) activity in ALL patients with poor response to
this drug. LCK can also play important roles for developing new thera-
pies for ALL patients resistant to prednisone. In addition, Cyclin E is
highly expressed in patients suffering relapses at early-phases of the
therapy. Thus, there is an important relationship between high level of
Cyclin E and relapse incidence. This issue can be complemented via
shotgun oncoproteomics with future research as it remains critical
for improving therapy for ALL patients with relapses [15].
Spleen tyrosine kinase (SYK) is a key molecule controlling apop-
tosis related to the activation of PI3-K/AKT, NFjB and STAT3 anti-
apoptotic signalling pathways in leukaemia type B. Uckun and Qazi
[16] carried out a research study where they proposed that SYK
might overcome the resistance of malignant B-lineage lymphoid cells
to apoptosis providing the theory for more effective multi-modality
treatment-therapy regimens for poor prognosis B-precursor ALL
(BPL). Radiation by ionizing and different types of chemotherapeutic
drugs used in BPL therapy produces DSB in nuclear DNA triggering
apoptotic cell death. NFjB and PI3-K survival signalling pathways are
activated by chemotherapeutic agents and contribute to drug resis-
tance of leukaemic cells. In addition, NFjB and PI3-K signalling path-
ways are regulated by tyrosine kinase SYK. SYK phosphorylates SLP-
65/BLNK (B-cell linker) are an integral part of effective pre-breaking-
point cluster region (BCR) signalling in BCPs as well as BCR signal-
ling in mature B lymphocytes. SYK plays a relevant regulatory
function in early specification and maturation events during B-cell
ontogeny. Inhibition of SYK blocks BCR and mTOR signalling path-
ways, leading to apoptotic death of leukaemic cells. In addition, SYK
has another anti-apoptotic role related to leukaemic precursor B cells
at the early stages of B-cell (human) ontogeny. Inhibition of SYK trig-
gers apoptosis in primary leukaemic cells from BPL patients who are
also resistant to therapy. They carried out studies using a liposomal
nanoparticle formulation of a SYK substrate-binding site inhibitor
called C61. C61 is coming from ‘nanomedicine’ potential candidate
for poor prognosis cases and for relapses BPL cases. C61 was suc-
cessfully tested in mice as it was able to induce apoptosis in radia-
tion-resistant primary leukaemic cells coming from BPL patients.
Uckun and Qazi [16] propose that C61 may be a useful strategy for
innovations against ALL therapy refractory. When combining this
important current ALL research study to proteomic strategies, signal-
ling networks involved in ALL progression and affected by C61, could
be discovered; thus, key signalling molecules ALL can be identified
for good new specific target candidates [16].
When Notch signalling is abnormally activated/deactivated, this
implies a relevant oncogenic mechanism for ALL T cells. ALL subtype
T is commonly quite aggressive, especially for disease in children. Lin
and coworkers [13] via proteomic assays identified DDX5, an ATP-
dependent DEAD-box RNA helicase, and MAML1 protein. DDX5 has
been shown to be associated with the endogenous NOTCH1 transcrip-
tion activation complex in human T-ALL leukaemic cells. Thus, unrav-
elling the molecular regulation of Notch signalling is crucial to identify
new approaches to block aberrant Notch oncogenic activity during
ALL progression. MAML transcriptional activator is critical for
signalling activation of Notch. Indeed, MAML1 is the one involved in
the regulation of Notch in leukaemic cells although its mechanism
remains unknown. Lin et al. [17] also proved that lentivirus-mediated
short-hairpin RNA knock-down of DDX5 was because of low expres-
sion of Notch target genes, decreased cell proliferation and increased
apoptosis in cultured human leukaemic cells together with signalling
of Notch activation. This study demonstrates that DDX5 is pushing
for useful Notch-mediated transcription in leukaemic cells. Therefore,
DDX5 can be a future potential new target therapy for regulating
Notch signalling in leukaemia [17].
PI3K/AKT pathway mutations have been found in T-cell ALL. Never-
theless, their relevance related to other genetic aberrations is not yet
clear. PTEN mutations are proposed as secondary mutations which fol-
low NOTCH1-activating mutations and later on, they can produce cellu-
lar resistance to c-secretase inhibitors. Zuurbier et al. [18] investigated
the role of PTEN, PI3K and AKT aberrations in paediatric T-cell leukae-
mia patient cohort (n = 146) treated on DCOG or COALL protocols. The
authors discovered that PTEN and AKT E17K aberrations appeared in
around 13% and 2% of patients respectively. They realized that PTEN/
AKT mutations appeared in a high percentage in TAL- or LMO-rear-
ranged leukaemia, although PTEN/AKT mutations did not appear in
TLX3-rearranged patients (P = 0.03). The opposite data resulting was
obtained for NOTCH1-activating mutations. In addition, Zuurbier et al.
[14] detected that T-cell leukaemia patients without PTEN/AKT and
NOTCH1-activating mutations fared well, with a cumulative incidence of
relapse of only 8% versus 35% for PTEN/AKT and/or NOTCH1-activated
patients (P = 0.005). This is critical and important information related
to the significance of PTEN and AKT aberrations in paediatric T-cell ALL.
Applying quantitative phosphoproteomics strategies to peripheral blood
and bone marrow ALL, several signalling pathways (and networks) can
be captured in a single experiment. Therefore, hundreds of phosphory-
lated protein kinases can be detected if they are working well during
ALL or we can even get those which do not operate properly from each
ALL patient evolution. This is key information for patients suffering
relapses and resistance or toxicity to the current ALL treatments [18].
Braoudaki et al. [19] developed proteomic studies to see the dif-
ferential proteins expressed when comparing low- and high-risk
patients suffering ALL. Cytogenetic assays were carried out in parallel
to proteomics to get complementary data for clinical advances. Pro-
teins were extracted from bone marrow and peripheral blood plasma
of patients who belong to high- and low-risk ALL at diagnosis. They
applied 2DE (2 Dimentional Electrophoresis) coupled to MALDI-MS/
MS analysis and, later on, the differentially expressed proteins
detected were validated via Western blot. Proteins Clus, Ceru, ApoE,
ApoA4, ApoA1, Gels, S10A9, Ambp, Actb, Cata and Afam have an
important role in leukaemia prognosis, mainly as distinctive signals
for aggressive leukaemia cases. None of these identified biomarkers
for ALL, as distinctive signals for aggressive cases, are currently eval-
uated routinely at hospitals. It could be interesting to check the previ-
ously resulting data of Braoudaki et al. [15] for each patient when he/
she is diagnosed with ALL. If more patients could be checked for
these biomarkers, more statistical and clinical value would be
achieved, thus, ensuring true biomarkers useful for therapy improve-
ments. We would change 2DE for ESI-LC-MS as it is faster and with
higher accuracy despite the important ALL information provided [19].
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Peripheral blood plasma was shown to be a good sample to pre-
dict clinical behaviour in ALL patients irrespective of the percentage
of bone marrow blasts. Albitar et al. [20] analysed, via proteomics,
this clinic sample type from 57 patients suffering ALL before initiation
of therapy. They applied strong anion exchange coupled to protein
chip arrays and surface-enhanced laser desorption/ionization. It was
shown that recurrence prediction is independent to bone marrow
blast count, cytogenetic assays and surface markers. Thus, evolution
ALL responses of patients can be followed via proteomic tools to
cover gaps which nowadays are not explained by genotype–pheno-
type assays (Table 1).
Also, proteomic research in paediatrics is important and most of
the successes thus far are seen in research that utilize samples that
require less invasive procedures and focus on prevailing childhood
diseases such as ALL. Nevertheless, most of platelet proteome data
obtained to date are derived from the adult population and the poten-
tial of platelet proteomic application in children has not yet been
explored [21].
Future perspectives
Signalling networks do not operate in an independent way, as signal-
ling cascades are connected. Thus, we defined a space (bone mar-
rows and peripheral blood) and time-based strategies (at several
states of the patients) to understand the ALL evolution of each patient
and to capture the dynamics of phosphorylation events, from which
useful targets can be discovered for treating ALL.
A shotgun oncoproteomic strategy, space and time-based, using
sequential elution from immobilized metal affinity chromatography
(SIMAC) [22] and isobaric tag for relative and absolute quantitation
(iTRAQ) [23] coupled to liquid chromatography, electrospray ioniza-
tion, tandem mass spectrometry (LC-ESI-MS/MS) [24, 25] is pro-
posed to be applied in our research team by the Spanish Health
System (SNS) in collaboration with international research teams to
unravel signatures of ALL patients who do not respond well to treat-
ments compared to those who do.
SIMAC coupled to iTRAQ and LC-ESI-MS/MS will allow us to iden-
tify the up- and down-regulated phosphorylated proteins via highly
sensitive techniques. The resulting data should show us important
clinical and biological information of signalling networks involved in
ALL resistances and toxicities.
We expect that this research strategy will help to improve current
ALL treatments, especially for ALL patients with poor prognoses
(Figs 1 and 2). Flow-through routine analysis of blood for leukaemia
diagnose via oncoproteomics and putative visualization of oncoprote-
omics ALL resulting data to several patients at different ALL states
(diagnose, 14 days after treatment and at the end of the treatment)
are detailed in both figures. Comparing different ALL states per each
patient, ALL signatures evolution can be achieved, thus, unknown
ALL molecules which are not working properly can be detected. In
fact, when comparing the resulting data from ALL patients with good
and poor prognosis, distinctive signatures involved in ALL progres-
sion can be identified. Therefore, therapy innovations can be
achieved. As delegate of HUPO, for human proteome on children ALL
studies at Hospital Universitario Ni~no Jesus, we are pursuing to
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Fig. 1 Flow-through routine analysis of blood for leukaemia diagnose via oncoproteomics. Blood samples from acute lymphoblastic leukaemia (ALL)
patients are routinely analysed by microscopy, cytometry, FISH, karyotype and polymerase chain reaction. These assays are well-established to
detect leukaemic cells, specific translocations and rearrangements. The ALL treatment is adequate according to the genetic data (with high or low
chemotherapy dose according to the high, intermediate and low risk of relapse). When combining those previously routine assays to shotgun prote-
omic analyses for each patient, coupling SIMAC, iTRAQ and ESI-LC-MS/MS, real protein biomarkers of ALL evolution per each patient can be dis-
covered. Thus, new therapy innovations may appear.
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support the human proteome in this context. We envision this will fur-
ther benefit the understanding of the pathology of the disease and
ultimately improve the diagnoses and personalized treatment.
Selected/multiple reaction monitoring [26–28], Western blotting
and ELISA assays can also help to validate identified signatures for
each ALL patient from shotgun oncoproteomic strategies.
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Fig. 2 Putative visualization of oncoproteomics ALL resulting data to several patients at different acute lymphoblastic leukaemia (ALL) states (diagnose,
14 days after treatment and at the end of the treatment). Comparing different ALL states per each patient, ALL signatures evolution can be achieved,
thus, unknown ALL molecules which are not working properly can be detected. In addition, when comparing the resulting data from ALL patients with
good and poor prognosis, distinctive signatures involved in ALL progression can be identified. Therefore, therapy innovations can be achieved.
• Establish  ALL clinical goal
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cytometry and ALL translocations)
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Fig. 3 Schedule from clinical to oncoproteomics and bioinformatics analyses. Once the clinical goal and human body fluids have been selected from
ALL patients, efficient shotgun oncoproteomics must be established and be coupled to bioinformatic tools, which can be applied for the potential
development of personalized approaches, aimed at the concept of personalized ALL medicine. After long and tedious assays, new ALL targets can
be discovered, and database mining from new binding sites from ALL candidates can be created. Also, verification of side effects and toxicities for
the new ALL molecules have to be studied, to validate a new ALL drug candidate.
50 ª 2014 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
The resulting data per patient can be correlated and linked to other
patients. Thus, a ‘library’ collection of ALL evolution for patients can
be set-up, which will help to ultimate a reference, once a statistically
significant number of ALL patients is studied.
Once the phosphorylation state of network proteins, constitutive
or associated to ALL evolution is established by shotgun oncoproteo-
mics, a range of bioinformatic methods permits deeper study of its
properties and contacts. Using sequence analysis, sequence compari-
son, virtual approaches of protein–protein, protein–ligand interaction
or molecular dynamics simulations, initial physical information can be
applied for the potential development of personalized approaches,
aimed at the concept of personalized ALL medicine. Bioinformatics
covers a wide spectrum of techniques for the generation and use of
beneficial information from structure, sequence or relationships
among biological items (DNA, RNA, proteins, macromolecular com-
plexes, etc.) [29, 30]. Those most useful in clinical ALL studies are:
Ascore and PhosphoScore (statistical algorithms which measure the
probability of correct phosphorylation site localization based on the
presence and intensity of site-determining ions in MS2 spectra), and
next-generation sequencing (NGS) was used in a detailed study of
genes involved in colorectal cancer [31]. As a main conclusion of the
study, the authors stated that sequencing of whole tumour exomes
allowed prediction of the microsatellite status of trinucleotide CGC,
facilitating, at the same time, the putative finding of relevant muta-
tions. NGS can be applied to formalin-fixed and paraffin-embedded
material, allowing the renewed study of all the ancient material stored
in the pathology departments), sequence-to-sequence and sequence-
to-structure comparisons (multiple sequence analysis) to obtain valu-
able information on the nature of the functional implications of the
mutated residues in the protein ALL context. Homology modelling 3D
structure of the active centre of a protein of interest (in absence of
experimental crystal structures, the homology modelling methods),
can develop a 3D model from a protein sequence based on the struc-
tures of a crystallized homologous protein. Information on the 3D
structure of the active centre of a protein of interest and/or its natural
ligands can be used as a basis for the design of effective drugs and
the more sophisticated rational drug design and molecular dynamics
techniques. Using shotgun oncoproteomics together with structural
analysis of proteins and bioinformatic tools, important biological
understanding of ALL evolution can be achieved. Prototypical shotgun
oncoproteomic coupled to bioinformatics pipeline useful for clinical
ALL research is illustrated [32, 33] (Fig. 3). In the schedule of Fig-
ure 3, it is illustrated in a simple manner that firstly, the clinical goal
and human samples have to be established and selected from ALL
patients; secondly, an efficient shotgun oncoproteomics must be
designed and coupled to bioinformatic tools to get biomarkers for a
given clinical issue, and to arrange the resulting data. From the result-
ing data, potential ALL new targets can be achieved, and therefore
new ALL drug candidates can be designed and validated. In fact, veri-
fication of side effects and toxicities for the new ALL molecules have
to be studied, to validate a new ALL drug candidate, aimed at the con-
cept of personalized ALL medicine.
Conclusions
Network proteins with distinctive characteristics for ALL patients,
unrevealed through cytogenetics, are currently an important source
of novel therapeutic targets that emerge from shotgun proteomics.
Shotgun oncoproteomics and bioinformatic strategies need to be
combined to achieve the personalized medicine. Studies of reversible
phosphorylation in proteins from ALL networks will allow the genera-
tion of models for protein–protein contacts at the molecular level tak-
ing into account each particular protein sequence. Molecular dynamic
analysis of those contacts will allow the modification of the 3D com-
puter models obtaining virtual structures tailored to individual
patients. So, we should get, according to the resulting structure infor-
mation, new drug candidates for adapting the therapies; and innovate
new ALL treatments. In fact, the ALL evolution per each patient can
be studied via shotgun oncoproteomics, thus ALL patients can be
benefited.
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